[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"microbiota\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:microbiota":31},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,28,0,25,[9,48,73,98,120,146,176,203,241,263,285,310,339,371,412,458,487,511,536,563,588,610,633,659,681],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":16,"eligibilityCriteria":17,"healthyVolunteers":18,"sex":19,"minAge":20,"maxAge":21,"enrollmentInfo":22,"targetDuration":4,"studyType":25,"phases":26,"briefSummary":28,"conditions":29,"keywords":33,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100643424","health-effects-of-ultra-processed-food-intake-100643424",false,"NCT07634159","Health Effects of Ultra-processed Food Intake","Health Effects of Ultra-processed Food Intake: a Randomized Crossover Feeding Study","UPFront","Inclusion Criteria:\n\n* Age 20-60 years\n* Weight stable (less than 5% weight change in the past 3 months)\n* No plans to change weight\n* Willing to eat the study diet and a mixed diet\n* Has provided informed consent to participate in the study\n\nExclusion Criteria:\n\n* Allergy or intolerance to foods included in the study. Participants with lactose intolerance treated with lactase may participate if they take enzymes.\n* BMI \\\u003C18.5 or \\>35 kg\u002Fm²\n* Use of medications known to significantly affect appetite (e.g., oral corticosteroids, antipsychotic medications, or GLP-1 receptor agonists)\n* Use of lipid-lowering medications (e.g., statins or PCSK9 inhibitors)\n* Diagnosed diabetes or capillary blood glucose at or above 12.2 mmol\u002FL\n* Disease associated with malabsorption (e.g., inflammatory bowel disease or celiac disease)\n* Previous bariatric surgery\n* Established cardiovascular disease (heart failure, myocardial infarction, or stroke) or cancer\n* Pregnancy or breastfeeding, or plans to become pregnant or breastfeed during the study",true,"ALL","20 Years","60 Years",{"count":23,"type":24},40,"ESTIMATED","INTERVENTIONAL",[27],"NA","Ultra-processed food (UPF) intake has been related to negative health effects and incresed energy intake in previous intervention studies. Thus, previous studies have seen weight gain from higher UPF intake which obscures the potentital to see effects on cardiometabolic biomarkers, independent of weight changes. The overall aim of this project is to study the causal effects of a high UPF diet, compared to a nutrient-matched low UPF diet, on appetite and cardiometabolic health in a weight-stable context.",[30,31,32],"Cardiometabolic Risk Factors","Microbiota","Diet Interventions",[34],"Ultra-processed food","NOT_YET_RECRUITING","2026-06-03",{"date":38,"type":39},"2026-06-08","ACTUAL",{"date":41,"type":24},"2026-08",{"date":43,"type":24},"2027-12",{"name":45,"class":46},"Göteborg University","OTHER",1,{"id":49,"slug":50,"hasResults":12,"nctId":51,"briefTitle":52,"officialTitle":52,"acronym":53,"eligibilityCriteria":54,"healthyVolunteers":12,"sex":19,"minAge":55,"maxAge":4,"enrollmentInfo":56,"targetDuration":4,"studyType":25,"phases":58,"briefSummary":59,"conditions":60,"keywords":4,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":47},"100598754","non-interventional-study-exploring-the-composition-of-the-valvular-microbiota-of-patients-undergoing-cardiac-surgery-100598754","NCT07075601","Non-interventional Study Exploring the Composition of the Valvular Microbiota of Patients Undergoing Cardiac Surgery","BIOVALV","Inclusion Criteria:\n\n* Male or female patient.\n* Present an indication for cardiac surgery that requires explantation of the aortic valve.\n* Be able to receive information about the study process and understand the study participation information form.\n* State their non-opposition to participating in the study.\n\nExclusion Criteria:\n\n* Patients infected with HIV\n* Age under 18\n* Under court supervision, guardianship, or curatorship\n* Patients with a history of infective endocarditis.","18 Years",{"count":57,"type":24},200,[27],"The prevalence of aortic valve disease is increasing, with these valvulopathies present in half of individuals over the age of 65.\n\nOberbach A. et al (1) demonstrated the presence of microbiota in 52% of cases of explanted aortic valves. One current hypothesis is the role of this microbiota in the pathophysiology of these degenerative valve diseases. This microbiota is probably not completely eradicated after resection of the native valve and implantation of a conventional prosthesis; it is even left in place during percutaneous aortic valve implantation, during which the prosthesis is deployed within the native valve. It could therefore also play a role in the occurrence of postoperative complications and the degeneration or thrombosis of a bioprosthesis.\n\nFurthermore, recent clinical and epidemiological studies have shown a link between oral infections and cardiovascular diseases. As recommended by the HAS, these patients require multidisciplinary care, involving cardiologists, cardiac surgeons and general practitioners, as well as careful oral and dental care and monitoring provided by specialists in oral pathologies and oral care. The accumulation of bacterial plaque on the surface of the tooth and certain oral bacteria causes the development of periodontal pockets which are characteristic of periodontitis. Bacteria, microbial products and inflammatory mediators produced locally can then enter the bloodstream and affect distant organs such as the cardiovascular system. The recommendations of the European Society of Cardiology are therefore to carry out regular oral and dental consultations to prevent the risk of infection. Therefore, within the Toulouse University Hospital, a care network has been set up for patients with cardiovascular pathologies, in order to improve their access to dental care, screening and management of oral diseases. For the past year, patients hospitalized in the cardiology departments have been seen in consultation in the dental department of the Toulouse University Hospital.",[61,62,31],"Valvulopathy","Cardiac Surgery","RECRUITING","2026-05-28",{"date":66,"type":39},"2026-06-01",{"date":68,"type":39},"2025-11-19",{"date":70,"type":24},"2029-08-31",{"name":72,"class":46},"University Hospital, Toulouse",{"id":74,"slug":75,"hasResults":12,"nctId":76,"briefTitle":77,"officialTitle":77,"acronym":4,"eligibilityCriteria":78,"healthyVolunteers":18,"sex":79,"minAge":55,"maxAge":80,"enrollmentInfo":81,"targetDuration":4,"studyType":25,"phases":83,"briefSummary":85,"conditions":86,"keywords":4,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":88,"lastUpdatePostDateStruct":89,"startDateStruct":91,"completionDateStruct":93,"leadSponsor":95,"locationsCount":97},"100542815","phase-1-the-effect-of-oral-gan-shuangbi-during-the-perinatal-period-on-the-recovery-of-intestinal-function-after-cesarean-section-in-pregnant-women--a-multicenter-double-blind-randomized-controlled-clinical-trial-100542815","NCT06347770","The Effect of Oral Gan Shuangbi During the Perinatal Period on the Recovery of Intestinal Function After Cesarean Section in Pregnant Women- A Multicenter, Double-blind, Randomized Controlled Clinical Trial","Inclusion Criteria:\n\n* Chinese woman who is pregnant with a single fetus\n* Pregnant women who planned to perform lower section of uterus due to social factors, relative head basin asymmetry, macrosomia, cicatricial uterus and other reasons.\n\nExclusion Criteria:\n\n* Gastrointestinal disease or family history\n* Antibiotic usage during pregnancy\n* Habit of eating foods with high probiotic content such as yogurt and cheese during pregnancy\n* Take other probiotics or probiotic drinks during pregnancy regularly\n* Hypertension, Diabetes Mellitus, Hyperthyroidism, Hypothyroidism, Autoimmune Disease, or Other Endocrine and Metabolic Disease\n* Transfusion History, Organ Transplantation History or Immunotherapy\n* Gestational hypertension, gestational diabetes, gestational thyroid dysfunction and other endocrine and metabolic diseases occurred during this pregnancy.","FEMALE","45 Years",{"count":82,"type":24},404,[84],"PHASE1","This study aims to evaluate the effect of probiotics 7 days before cesarean section (CS) on postoperative recovery and the change of gut microbiota in pregnant women. Samples were obtained from a total of 202 pregnant individuals, divided into control group and probiotics group. Anal exhaust time and first defecating time were set as the primary outcome of recovery of CS.",[31,87],"Postoperative Recovery","2026-04-12",{"date":90,"type":39},"2026-04-15",{"date":92,"type":39},"2024-01-08",{"date":94,"type":24},"2028-03-31",{"name":96,"class":46},"Zhe Li",2,{"id":99,"slug":100,"hasResults":12,"nctId":101,"briefTitle":102,"officialTitle":102,"acronym":4,"eligibilityCriteria":103,"healthyVolunteers":18,"sex":19,"minAge":104,"maxAge":105,"enrollmentInfo":106,"targetDuration":4,"studyType":25,"phases":108,"briefSummary":109,"conditions":110,"keywords":4,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":111,"lastUpdatePostDateStruct":112,"startDateStruct":114,"completionDateStruct":116,"leadSponsor":118,"locationsCount":47},"100633625","effect-of-consuming-a-mango-and-chia-based-beverage-on-modulating-the-intestinal-microbiota-in-obese-children-100633625","NCT07529119","Effect of Consuming a Mango and Chia-based Beverage on Modulating the Intestinal Microbiota in Obese Children","Inclusion Criteria:\n\n100 children aged 8-16 years from Paraguay, stratified by BMI (with\u002Fwithout excess weight).\n\nExclusion Criteria:\n\nAllergyc to mango or chia","8 Years","16 Years",{"count":107,"type":24},100,[27],"This randomized clinical trial evaluates the effect of a mango and chia-based beverage on gut microbiota modulation in 100 Paraguayan children aged 8-16 years with obesity. Participants will consume the intervention beverage for 6 weeks. Fecal samples will be collected before and after each intervention to analyze microbiota composition using 16S rRNA sequencing. This study aims to characterize the gut microbiota of Paraguayan children for the first time and assess whether this functional beverage can positively modulate intestinal bacteria as a potential strategy to address childhood obesity, which affects 1 in 3 school-age children in Paraguay.",[31],"2026-04-07",{"date":113,"type":39},"2026-04-14",{"date":115,"type":39},"2026-02-09",{"date":117,"type":24},"2026-07",{"name":119,"class":46},"Universidad Nacional de Caaguazu",{"id":121,"slug":122,"hasResults":12,"nctId":123,"briefTitle":124,"officialTitle":124,"acronym":125,"eligibilityCriteria":126,"healthyVolunteers":18,"sex":19,"minAge":127,"maxAge":128,"enrollmentInfo":129,"targetDuration":4,"studyType":25,"phases":131,"briefSummary":132,"conditions":133,"keywords":4,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":137,"lastUpdatePostDateStruct":138,"startDateStruct":140,"completionDateStruct":142,"leadSponsor":144,"locationsCount":47},"100628378","effects-of-cranberry-on-gut-and-metabolic-health-100628378","NCT07460856","Effects of Cranberry on Gut and Metabolic Health","CRANOS","Inclusion Criteria:\n\n* body mass index between 25 and 40 kg\u002Fm2\n* at least one of the following criteria: fasting plasma insulin \\>60 pmol\u002FL, fasting glycemia between 5.5 and 6.9 mmol\u002FL, glycated hemoglobin (HbA1c) level of 5.7- 6.4% and\u002For fasting triglyceride \\>1.35 mmol\u002FL.\n\nExclusion Criteria:\n\n* to have aversion to cranberry products\n* regularly drinking alcohol (\\>2 glasses\u002Fday)\n* having a significant change in body weight in the past 3 months (±5% of their body weight) due to bariatric surgery or other conditions\n* taking medication which may affect the study outcomes (i.e. antidiabetic and\u002For cholesterol or lipid-lowering medications and\u002For glucocorticosteroid in supraphysiological doses and\u002For anti-obesity medications)\n* taking regular probiotics and prebiotics (including fruit\u002Fberry polyphenol supplements) in the past 3 months\n* having eating disorders\n* had undergone major surgery 3 months prior to the study or if they had one planned\n* if they had intestinal malabsorption, cirrhosis or chronic kidney disease\n* being pregnant, planning a pregnancy, or breastfeeding.","25 Years","70 Years",{"count":130,"type":24},73,[27],"The consumption of plant-based foods, particularly berries, has been associated with improved health due to their high content of bioactive compounds. Among these, polyphenols-especially proanthocyanidins (PACs)-may offer protective effects against chronic diseases related to overweight and obesity. Cranberries are naturally rich in PACs and may positively influence metabolic health by modulating the gut microbiota. However, their specific effects on intestinal integrity and broader metabolic outcomes remain underexplored.\n\nThe primary aim of this study is to assess the effects of cranberry supplementation on glucose metabolism, insulin sensitivity, blood lipid levels, and the composition and function of the gut microbiota in overweight and obese individuals.\n\nThis randomized, double-blind, placebo-controlled, crossover clinical trial will include two 12-week intervention periods-one with a cranberry beverage and one with a placebo-separated by a 4-week washout period and preceded by a 2-week lifestyle stabilization phase. Participants will undergo comprehensive metabolic assessments (glucose control, insulin sensitivity, lipid profile), body composition analysis, gut microbiota profiling, and liver fat imaging (MRI in a subsample of female participants). Additional evaluations will include markers of inflammation, appetite regulation, intestinal health, and lifestyle factors.",[134,135,136,31],"Overweight\u002FObesity","Metabolic Syndrome","Insulin Resistance","2026-03-04",{"date":139,"type":39},"2026-03-10",{"date":141,"type":39},"2025-07-07",{"date":143,"type":24},"2026-12",{"name":145,"class":46},"Laval University",{"id":147,"slug":148,"hasResults":12,"nctId":149,"briefTitle":150,"officialTitle":151,"acronym":4,"eligibilityCriteria":152,"healthyVolunteers":12,"sex":19,"minAge":153,"maxAge":4,"enrollmentInfo":154,"targetDuration":4,"studyType":156,"phases":4,"briefSummary":157,"conditions":158,"keywords":162,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":167,"lastUpdatePostDateStruct":168,"startDateStruct":170,"completionDateStruct":172,"leadSponsor":174,"locationsCount":97},"100433483","ins-b-cells-and-microbiota-100433483","NCT04924712","INS, B Cells and Microbiota","Controlled Multicenter Epidemiological Study of Peripheral Leukocyte Populations and Microbiota in Patients With Idiopathic Nephrotic Syndrome (INS)","Inclusion Criteria :\n\n* Patient treated in participating centers\n* In nephrotic attack, defined biologically by:\n\nProteinuria \\> 3g 24h or A proteinuria\u002Fcreatinuria ratio \\> 3 or Defined at the discretion of the clinician\n\nNon inclusion Criteria :\n\n* Patient with a history of NIS flare-ups resistant to corticosteroid therapy\n* Patient treated with immunosuppressant\n* Patient treated with corticosteroids \\> 10 mg\u002Fd\n* Weight \\\u003C50 kg\n* Pregnant woman\n* Patient under guardianship \u002F curatorship","12 Years",{"count":155,"type":24},30,"OBSERVATIONAL","Idiopathic nephrotic syndrome (NIS) is a clinical entity defined by the association of selective albuminuria, hypoalbuminemia, and nonspecific glomerular lesions (lesions minimal glomerular (LGM) or segmental and focal hyalinosis (HSF). The complication of this kidney disease is the progression towards chronic renal failure and in case of kidney transplantation, its immediate recurrence on the graft . The origin of this syndrome is unknown but a number of clinical observations tend to show an involvement of immune system. A link has been highlighted between atopy, diet and nephrotic flare-ups. The speed of recurrence of this initial disease on the graft and the observation of remissions obtained after treatment by plasma exchange or immunoadsorptions support the presence of a pathogenic plasma factor. Anti-CD20 treatments depleting B lymphocytes has made it possible to favorably treat a number of patients. Dysfunction of regulatory T cells has also been shown in SNI patients. This modification seems linked to allergies and could be due to an aberrant microbiota. The hypothesis of causality between dysbiosis, alteration lymphocyte and triggering of an SNI was mentioned recently. Two studies have shown intestinal dysbiosis in pediatric SNI\u002FLGM, with reduction of T circulating regulators",[31,159,160,161],"B-lymphocytes","Glomerulosclerosis","T-lymphocytes",[163,164,31,165,166],"Idiopathic Nephrotic Syndrome","Focal Segmental Glomerulosclerosis","B Lymphocytes","Regulatory T cells","2026-02-27",{"date":169,"type":39},"2026-03-03",{"date":171,"type":39},"2022-01-18",{"date":173,"type":24},"2027-01-18",{"name":175,"class":46},"Nantes University Hospital",{"id":177,"slug":178,"hasResults":12,"nctId":179,"briefTitle":180,"officialTitle":181,"acronym":4,"eligibilityCriteria":182,"healthyVolunteers":18,"sex":19,"minAge":183,"maxAge":184,"enrollmentInfo":185,"targetDuration":4,"studyType":25,"phases":187,"briefSummary":188,"conditions":189,"keywords":4,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":193,"lastUpdatePostDateStruct":194,"startDateStruct":196,"completionDateStruct":198,"leadSponsor":200,"locationsCount":47},"100618581","flourish-exploring-the-early-infant-gut-microbiome-100618581","NCT07333482","Flourish: Exploring the Early Infant Gut Microbiome","Flourish Study: A Randomized, Three-Arm Longitudinal Clinical Study of Microbiome-Guided Interventions in Cesarean-Born Infants","Inclusion Criteria:\n\n* Infants are qualified for this study if they are 0 to 3 months of age at time of enrollment.\n* Infants must have been delivered via Cesarean delivery (C-section), either scheduled or emergent.\n* Infants must have been at least 36 weeks gestation at time of delivery.\n* Infants and their caregivers must reside in the United States with a US mailing address.\n\nExclusion Criteria:\n\n* Infants can not have been given probiotic supplements in their life at recruitment. This includes probiotic powder or supplements or formula with probiotic addition or multivitamin with probiotic addition.\n* Twin and multiple birth infants are not accepted in this study.\n* Infants cannot have the following existing health conditions:\n* Gastrointestinal conditions: Hirschsprung disease, eosinophilic gastrointestinal disorders (EGID) including eosinophilic esophagitis (EoE), necrotizing enterocolitis (NEC), short bowel syndrome (SBS)\n* Immune or auto-immune conditions: Severe Combined Immunodeficiency (SCID), human immunodeficiency virus (HIV)), excluding eczema and rashes\n* Congenital conditions: cleft lip or cleft palate, congenital heart disease, cerebral palsy, fragile X syndrome, down syndrome, spina bifida, cystic fibrosis, phenylketonuria (PKU), congenital hypothyroidism (CHT), galactosaemia)\n* Blood disorders (sickle cell disease, thalassemia, hemophilia)\n* Infant or any immediate family member has previously received results from an at-home microbiome stool test (excluding standard clinical diagnostic testing such as stool culture or pathogen testing)","0 Months","3 Months",{"count":186,"type":24},250,[27],"The goal of this clinical trial is to learn whether microbiome analysis, education, and personalized recommendations can improve gut health and reduce early markers of immune-related conditions in infants aged 0-3 months delivered via Cesarean section. The study aims to determine whether these interventions can increase beneficial bacteria, decrease C-section-associated microbiome signatures, reduce opportunistic pathogens, and improve functional potential for HMO digestion and SCFA production. The study also seeks to assess whether improvements in microbiome composition are associated with a reduced prevalence of early atopic symptoms.\n\nResearchers will compare three groups: a full intervention arm that receives microbiome reports, coaching, personalized recommendations, and educational materials; a limited intervention arm that receives simplified reports and basic recommendations; and a control arm that receives no results until study completion. This design allows evaluation of both a comprehensive intervention and a more scalable, minimal-results model.\n\nParticipants will:\n\n1. Provide six microbiome stool samples over a 24-month period.\n2. Provide additional small stool samples at two timepoints for exploratory metabolomic analysis.\n3. Receive microbiome reports and guidance according to their assigned study arm.\n4. Complete surveys on infant health history, symptoms, diet, and environmental exposures.\n5. Participate in standardized eczema assessment(s) administered by a Nurse Practitioner and evaluated by a Pediatric Allergy Specialist if any symptoms are reported.\n\nThis study seeks to demonstrate that targeted microbiome support can positively shift gut microbial development in C-section infants and may reduce risks linked to the early stages of the atopic march. Findings may inform scalable strategies for delivering microbiome-based support in early life and improve long-term health outcomes for this high-risk population.",[31,190,191,192],"Gut Microbiome","Eczema","Microbiome","2026-02-20",{"date":195,"type":39},"2026-02-24",{"date":197,"type":39},"2026-01-31",{"date":199,"type":24},"2028-09",{"name":201,"class":202},"Seeding Inc","INDUSTRY",{"id":204,"slug":205,"hasResults":12,"nctId":206,"briefTitle":207,"officialTitle":208,"acronym":209,"eligibilityCriteria":210,"healthyVolunteers":12,"sex":79,"minAge":55,"maxAge":4,"enrollmentInfo":211,"targetDuration":4,"studyType":25,"phases":212,"briefSummary":213,"conditions":214,"keywords":221,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":233,"lastUpdatePostDateStruct":234,"startDateStruct":235,"completionDateStruct":237,"leadSponsor":239,"locationsCount":47},"100595200","effectiveness-of-coenzyme-q10-and-probiotics-in-periodontal-therapy-during-pregnancy-100595200","NCT07029360","Effectiveness of Coenzyme Q10 and Probiotics in Periodontal Therapy During Pregnancy","Adjunctive Use of Coenzyme Q10 and Probiotics to Improve Periodontal Health in Pregnant Women: A Randomized Controlled Trial","PREG-Q10","Inclusion Criteria:\n\n* Pregnant women between the 4th and 8th month of gestation\n* Age ≥ 18 years\n* Able to understand and communicate in Italian and\u002For English\n* Willing to provide written informed consent\n* Good compliance and willingness to follow study instructions\n\nExclusion Criteria:\n\n* Presence of cardiac pacemakers\n* Diagnosed psychological, neurological, or psychiatric disorders\n* Ongoing oncological therapy\n* Use of bisphosphonates within the last 12 months\n* Poor motivation or low compliance\n* Substance abuse (drugs or alcohol) or lifestyle incompatible with study requirements",{"count":23,"type":24},[27],"This randomized controlled clinical trial aims to evaluate the effectiveness of adjunctive coenzyme Q10 and probiotic supplementation (Limosilactobacillus reuteri Prodentis®) in improving periodontal health in pregnant women undergoing non-surgical periodontal therapy. Forty participants will be randomly assigned to two groups: the test group will receive professional oral hygiene every three months along with a coenzyme Q10-based toothpaste and daily probiotic supplementation; the control group will follow the same protocol without probiotics. The primary outcome is the reduction of the Plaque Index (PI), while secondary outcomes include Bleeding on Probing (BoP), Probing Pocket Depth (PPD), Clinical Attachment Level (CAL), gingival inflammation (MGI, PMGI), plaque distribution (PCR%, API), and gingival recession (R). The study duration is 6 months. The goal is to assess whether this combined therapy can promote a balanced oral microbiota and enhance periodontal health during pregnancy.",[215,216,217,218,219,220,31],"Pregnancy","Periodontal Disease","Gingivitis","Dental Plaque","Probiotics","Coenzyme Q10",[222,223,220,218,224,217,225,31,226,227,228,229,230,215,231,219,232],"Bleeding on Probing","Clinical Attachment Loss","Gingival Inflammation","Limosilactobacillus reuteri","Non-Surgical Periodontal Treatment","Oral Microbiota","Periodontal Therapy","Plaque Control","Plaque Index","Pregnant Women","Randomized Controlled Trial","2026-02-19",{"date":193,"type":39},{"date":236,"type":39},"2025-07-01",{"date":238,"type":24},"2026-06-10",{"name":240,"class":46},"University of Pavia",{"id":242,"slug":243,"hasResults":12,"nctId":244,"briefTitle":245,"officialTitle":246,"acronym":247,"eligibilityCriteria":248,"healthyVolunteers":12,"sex":19,"minAge":55,"maxAge":4,"enrollmentInfo":249,"targetDuration":4,"studyType":25,"phases":251,"briefSummary":252,"conditions":253,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":255,"lastUpdatePostDateStruct":256,"startDateStruct":258,"completionDateStruct":259,"leadSponsor":261,"locationsCount":4},"100624565","gut-microbiota-modulation-with-synbiotics-after-acute-coronary-syndrome-100624565","NCT07411287","Gut Microbiota Modulation With Synbiotics After Acute Coronary Syndrome","Gut Microbiota Modulation With Synbiotics as Secondary Prevention After Acute Coronary Syndrome: A Randomized-Controlled Trial Pilot Study","SYMBIO-ACS","Inclusion Criteria:\n\n* Informed Consent as documented by signature\n* Adult patients capable of providing discernment informed consent\n* Recent (\\\u003C 1 week) diagnosis of acute coronary syndrome as defined in the last 2023 ESC guidelines and the Fourth universal definition of myocardial infarction, including unstable angina or myocardial infarction with or without ST-elevation, managed either with best guideline-directed medical therapy or percutaneous coronary intervention.\n\n  * Myocardial injury: Elevated cardiac troponins (cTn) value above the 99th percentile URL. The injury is considered acute if there is a rise and\u002For fall of cTn values.\n  * Unstable angina: Myocardial ischaemia at rest or on minimal exertion in the absence of acute cardiomyocyte injury\u002Fnecrosis. Prolonged (\\>20 min) angina at rest; new onset of severe angina; angina that is increasing in frequency, longer in duration, or lower in threshold; or angina that occurs after a recent episode of MI\n  * Type 1 myocardial infarction: Detection of a rise and\u002For fall of cTn values with at least one value above the 99th percentile URL and with at least one of the following: Symptoms of acute myocardial ischaemia; New ischaemic ECG change; Development of pathological Q waves; Imaging evidence of new loss of viable myocardium or new regional wall motion abnormality in a pattern consistent with an ischaemic aetiology;Identification of a coronary thrombus by angiography including intracoronary imaging or by autopsy\n* Mastering French or German or capacity to be helped with adequate translation\n\nExclusion Criteria:\n\n* Contraindications to symbiotics as listed in Section 3.5.5, that is: immunocompromised individuals, intensive care patients (or critical state), severe valvulopathiesvalvular heart diseases, endocarditis antecedent, known allergy, chronic intestinal diseases or risk factors for small intestine bacterial overgrowth (SIBO) (severe malabsorption or history of digestive surgery), or severe comorbidities (see under)\n* Severe hepatic or renal dysfunction (defined as eGFR \\\u003C30 mL\u002Fmin\u002F1,73 m², dialysis or Child-Pugh score class C)\n* Limited life expectancy (\\\u003C1 year) or progressive malignant disease\n* Type 2 myocardial infarction: Detection of a rise and\u002For fall of cTn values with at least one value above the 99th percentile URL, and evidence of an imbalance between myocardial oxygen supply and demand unrelated to acute coronary athero-thrombosis, requiring at least one of the following: Symptoms of acute myocardial ischaemia; New ischaemic ECG changes; Development of pathological Q waves; Imaging evidence of new loss of viable myocardium or new regional wall motion abnormality in a pattern consistent with an ischaemic aetiology.\n* Ongoing pre\u002Fprobiotic supplementation\n* Chronic antibiotherapy or within less than 3 months\n* Women who are pregnant or breast feeding\n* Intention to become pregnant during the course of the study\n* Lack of safe contraception, defined as: Female participants of childbearing potential, not using and not willing to continue using a medically reliable method of contraception for the entire study duration, such as oral, injectable, or implantable contraceptives, or intrauterine contraceptive devices, or who are not using any other method considered sufficiently reliable by the investigator in individual cases (Female participants who are surgically sterilised \u002F hysterectomised or post-menopausal for longer than 2 years are not considered as being of child bearing potential)\n* Known or suspected non-compliance, drug or alcohol abuse, dement patients not living in assisted nurse facility care or without supervised treatment administration\n* Inability to follow the procedures of the study, e.g. due to language problems, psychological disorders, dementia, etc. of the participant,\n* Previous enrolment into the current study,\n* Enrolment of the investigator, his\u002Fher family members, employees and other dependent persons",{"count":250,"type":24},80,[27],"Acute coronary syndrome (ACS) remains one of the leading causes of morbidity and mortality worldwide despite major advances in acute management and secondary prevention. Gut dysbiosis has been described as linked to cardiovascular events. Modulating the gut microbiota through symbiotics-a combination of probiotics and prebiotics-represents a promising, low-risk and widely accessible strategy to influence these pathways and contribute to the enhancement of cardiovascular prevention, with regards to the global burden as well as health costs.\n\nThe SYMBIO-ACS study is therefore designed to assess the effects of a symbiotic intervention on TMAO levels and identify new cardiometabolic biomarkers in patients following ACS, providing essential pilot data for future larger-scale preventive trials.",[254,31],"Atheroscleroses, Coronary","2026-02-11",{"date":257,"type":39},"2026-02-13",{"date":66,"type":24},{"date":260,"type":24},"2028-05-31",{"name":262,"class":46},"Centre Hospitalier de Bienne",{"id":264,"slug":265,"hasResults":12,"nctId":266,"briefTitle":267,"officialTitle":268,"acronym":4,"eligibilityCriteria":269,"healthyVolunteers":18,"sex":19,"minAge":270,"maxAge":55,"enrollmentInfo":271,"targetDuration":4,"studyType":25,"phases":272,"briefSummary":273,"conditions":274,"keywords":4,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":276,"lastUpdatePostDateStruct":277,"startDateStruct":279,"completionDateStruct":281,"leadSponsor":283,"locationsCount":47},"100625011","micro-brain-2024-study-on-pediatric-brain-tumors-100625011","NCT07417085","MICRO-BRAIN 2024: Study on Pediatric Brain Tumors","Implications and Applications of Microbiota in Pediatric Brain Tumors","Inclusion Criteria:\n\n* aged between 3 and 18 years with suspected CNS tumour undergoing neurosurgery (intracranial and spinal localisation)\n* Patients who have not undergone prolonged antibiotic or probiotic therapy in the three months prior to sample collection.\n* Signature of informed consent form.\n\nExclusion Criteria:\n\n* personal history of chronic inflammatory bowel disease (colitis, Crohn's disease, ulcerative colitis) and congenital or acquired gastrointestinal diseases (coeliac disease, diverticulitis and diverticulosis, peritonitis, Hirschsprung's disease, short bowel syndrome, intestinal malrotation or duplication, intestinal atresia, omphalocele, presence of stomas, acute gastroenteritis)\n* history of previous cancer-related treatments\n* diagnosis of brain tumour not confirmed by histology (data obtainable post-surgery)","3 Years",{"count":107,"type":24},[27],"In recent years, there has been growing interest in the human gut microbiota, whose health is characterised by high microbial diversity. Through the gut-brain axis, the microbiota influences the homeostasis of the central nervous system by regulating neurological, immune and epigenetic functions. Intestinal dysbiosis is associated with various neurological and oncological diseases, including paediatric diseases and colorectal cancer. Recent studies highlight a significant link between microbiota and brain tumours: cancer patients show reduced microbial richness and altered bacterial composition. In addition, an intratumoural microbial population has been identified that can influence tumour initiation, progression and response to therapies by modulating tumour cells and the immune system. The aim of this study is to analyse stool samples to study the microbiota in children suspected CNS brain tumor as there are currently no studies of this kind reported in the literature to assess whether microbial changes can be detected at diagnosis, can be found during the course of the disease or are associated with tumour progression.",[275,31],"Brain Tumor","2026-02-10",{"date":278,"type":39},"2026-02-18",{"date":280,"type":39},"2025-02-06",{"date":282,"type":24},"2027-10",{"name":284,"class":46},"Meyer Children's Hospital IRCCS",{"id":286,"slug":287,"hasResults":12,"nctId":288,"briefTitle":289,"officialTitle":290,"acronym":4,"eligibilityCriteria":291,"healthyVolunteers":12,"sex":19,"minAge":55,"maxAge":292,"enrollmentInfo":293,"targetDuration":4,"studyType":25,"phases":295,"briefSummary":296,"conditions":297,"keywords":299,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":301,"lastUpdatePostDateStruct":302,"startDateStruct":304,"completionDateStruct":306,"leadSponsor":308,"locationsCount":47},"100394607","capillary-endoscopy-aspiration-catheter-100394607","NCT04418258","Capillary Endoscopy Aspiration Catheter","Evaluation of a Capillary Endoscopy Aspiration Catheter","Inclusion Criteria:\n\n* Male or female subjects aged 18-85 undergoing esophagogastroduodenoscopy.\n\nExclusion Criteria:\n\n* There are no exclusion criteria for this study as subjects will be undergoing the procedures for medical reasons and not for the purposes of this study.","85 Years",{"count":294,"type":24},46,[27],"The small intestine is an understudied frontier of microbiome research. While aspiration during endoscopy is considered the gold standard to assess small bowel bacteria, the tools for sterile retrieval are primitive and poorly validated.\n\nEndoscopic aspiration is time-consuming and prone to contamination. Inspired by plants' ability to draw water by capillary action, a novel multi-capillary sterile system was designed which is a modified version of the conventional aspiration catheter.\n\nThe purpose of this study is to examine the time and volume capabilities of this catheter in suctioning various liquids compared to conventional aspiration catheter, in two groups, each includes 23 patients that going under endoscopy at GI lab at Cedars Sinai Medical Center. The investigator will collect up to 2 ml fluid from Duodenum- in first group by using the conventional catheter and in second group by using the capillary catheter. The time collection and the volume of samples in 2 groups will be compared.",[31,298],"SIBO",[300,298,190],"Endoscopy aspiration Catheter","2026-01-23",{"date":303,"type":39},"2026-01-26",{"date":305,"type":39},"2020-05-20",{"date":307,"type":24},"2027-06-01",{"name":309,"class":46},"Cedars-Sinai Medical Center",{"id":311,"slug":312,"hasResults":12,"nctId":313,"briefTitle":314,"officialTitle":314,"acronym":4,"eligibilityCriteria":315,"healthyVolunteers":18,"sex":19,"minAge":55,"maxAge":316,"enrollmentInfo":317,"targetDuration":319,"studyType":156,"phases":4,"briefSummary":320,"conditions":321,"keywords":325,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":330,"lastUpdatePostDateStruct":331,"startDateStruct":333,"completionDateStruct":335,"leadSponsor":337,"locationsCount":47},"100604796","comprehensive-analysis-of-gut-microbiota-signatures-in-metastatic-colorectal-cancer-100604796","NCT07154173","Comprehensive Analysis of Gut Microbiota Signatures in Metastatic Colorectal Cancer","Inclusion Criteria:\n\n* Age between 18 and 75 years\n* Pathologically confirmed colorectal cancer\n* Clearly defined clinical staging: including imaging or pathologically confirmed metastatic colorectal cancer (stage M1) and colorectal cancer without distant metastasis (stage M0)\n* Expected survival ≥ 3 months\n* Voluntary participation and signed informed consent\n\nExclusion Criteria:\n\n* Use of probiotics, antibiotics, or immunosuppressive agents within 1 month before surgery\n* Preoperative complete intestinal obstruction or gastrointestinal perforation\n* Intraoperative gastrointestinal perforation or tumor rupture\n* Previous history of gastrointestinal surgery (excluding colorectal cancer surgery, appendectomy, and cholecystectomy) or concurrent severe gastrointestinal diseases such as inflammatory bowel disease\n* Concurrent active systemic immune or infectious diseases, including severe allergies, rheumatoid arthritis, systemic lupus erythematosus, viral hepatitis, acquired immunodeficiency syndrome, etc.\n* Concurrent unhealed primary malignant tumors\n* Severe organ dysfunction or failure\n* Other conditions deemed unsuitable for this study by the investigator","75 Years",{"count":318,"type":24},300,"1 Year","Colorectal cancer (CRC) is one of the most common and deadly cancers worldwide. About 1 in 4 people with CRC already have cancer spread (metastasis) when first diagnosed, and about half develop spread during their illness. Recent research shows that bacteria living in the gut and even within tumors might play an important role in how cancer spreads.\n\nThe goal of this study is to better understand how bacteria might influence the spread of colorectal cancer. The main questions the investigators aim to answer are:\n\nAre there differences in bacteria between people whose cancer has spread and those whose cancer has not spread? Could certain bacteria help predict which cancers might spread?\n\nTo answer these questions, the investigators will:\n\nCollect different types of samples from participants:\n\nTumor tissue Normal tissue near the tumor Tissue from where cancer has spread Stool samples before surgery Study the bacteria in these samples using advanced testing methods Compare bacterial patterns between different groups\n\nPeople can take part in this study if they:\n\nAre between 18 and 75 years old Have colorectal cancer confirmed by doctors Have not taken antibiotics recently Do not have immune system problems\n\nThis research may help us:\n\nUnderstand why some colorectal cancers spread Find new ways to predict which cancers might spread Develop better treatments for colorectal cancer",[322,323,31,324],"Rectal Neoplasms","Colon Neoplasms","Metagenome",[326,327,328,329],"rectal neoplasms","colon neoplasms","microbiota","metagenomics","2025-12-26",{"date":332,"type":39},"2025-12-31",{"date":334,"type":39},"2025-01-01",{"date":336,"type":24},"2026-12-31",{"name":338,"class":46},"Sixth Affiliated Hospital, Sun Yat-sen University",{"id":340,"slug":341,"hasResults":12,"nctId":342,"briefTitle":343,"officialTitle":343,"acronym":344,"eligibilityCriteria":345,"healthyVolunteers":18,"sex":19,"minAge":346,"maxAge":347,"enrollmentInfo":348,"targetDuration":4,"studyType":156,"phases":4,"briefSummary":350,"conditions":351,"keywords":356,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":362,"startDateStruct":364,"completionDateStruct":366,"leadSponsor":368,"locationsCount":370},"100612447","epigut-epilepsy-and-gastrointestinal-microbiota-understanding-therapy-response-100612447","NCT07253701","EPIGUT: EPILEPSY AND GASTROINTESTINAL MICROBIOTA: UNDERSTANDING THERAPY RESPONSE","EpiGUT","Inclusion Criteria:\n\n* Patients: Age 2-79 years, newly diagnosed with epilepsy, treatment-naive at time of enrollment\n* Controls: Age 2-79 years\n\nExclusion Criteria:\n\n* Patients: already started ASM treatment (more then one dose), has used antibiotics or probiotics in the last three months, has a gastrointestinal diagnosis, has surgically removed parts of the GIT, obesity (BMI\\>30), T2D, follows a strict exclusion diet, is pregnant or breastfeeding, has a gastrostomy, PEG or jejunostomy\n* Controls: previous epilepsy diagnosis or ASM treatment, has used antibiotics or probiotics in the last three months, has a gastrointestinal diagnosis, has surgically removed parts of the GIT, obesity (BMI\\>30), T2D, follows a strict exclusion diet, is pregnant or breastfeeding, has a gastrostomy, PEG or jejunostomy","2 Years","79 Years",{"count":349,"type":24},1500,"The goal of this observational study is to learn how the bacteria in the gut and mouth (called the microbiota) are linked to different types of epilepsy and how they may affect how well seizure medicines work.\n\nResearchers want to answer two main questions:\n\nAre certain types of epilepsy linked to changes in the gut or mouth microbiota? Do the bacteria in the gut change how seizure medicines work for each person?\n\nEpilepsy is a brain condition that causes seizures. Even though there are many medicines for epilepsy, some people still have seizures or side effects. Studies in animals show that gut bacteria can raise or lower the chance of seizures. Smaller studies in people suggest the same thing, but they have been limited in size and scope.\n\nIn this study, researchers will collect biological samples from people who have newly diagnosed epilepsy and from people without epilepsy (called healthy controls). The samples will be tested to learn which bacteria are present. The researchers will then look for patterns that may explain which types of epilepsy are linked to changes in the microbiota.\n\nThe study will also look at whether the bacteria in the gut and mouth affect how well anti-seizure medicines (ASMs) work. For example, the researchers will explore if certain bacteria make medicines work better or worse.\n\nPatients will provide blood, stool and saliva samples. If collected for medical reasons, cerebrospinal fluid (CSF) - the clear liquid that surrounds the brain and spinal cord -will also be used.\n\nHealthy controls will provide stool and saliva samples only\n\nAll participants will be asked to fill an online questionnaire to share health and lifestyle information.\n\nPatients also allow researchers to confidentially access data from medical records related to diagnosis and treatment.\n\nBy comparing data from many participants across Sweden, researchers hope to understand how gut and mouth bacteria influence epilepsy and seizure control.\n\nThis research may help doctors in the future to use a person's microbiota profile to choose the best seizure medicine. The long-term goal is to improve seizure control, reduce side effects, and raise the quality of life for people living with epilepsy.",[352,31,353,354,355],"Epilepsy","Proteomics","Metabolomics","Biomarker Discovery",[357,358,359,360,361],"seizures","microbiome","anti-seizure medication","gut-brain-axis","epilepsy",{"date":363,"type":39},"2025-11-28",{"date":365,"type":39},"2024-02-27",{"date":367,"type":24},"2028-03",{"name":369,"class":46},"Karolinska Institutet",6,{"id":372,"slug":373,"hasResults":12,"nctId":374,"briefTitle":375,"officialTitle":375,"acronym":376,"eligibilityCriteria":377,"healthyVolunteers":18,"sex":19,"minAge":4,"maxAge":378,"enrollmentInfo":379,"targetDuration":4,"studyType":25,"phases":380,"briefSummary":381,"conditions":382,"keywords":396,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":403,"lastUpdatePostDateStruct":404,"startDateStruct":406,"completionDateStruct":408,"leadSponsor":410,"locationsCount":97},"100609268","infant-microbiota-restoration-with-maternal-microbes-100609268","NCT07212361","Infant Microbiota Restoration With Maternal Microbes","MaMi","Inclusion Criteria:\n\n* Healthy mother and healthy pregnancy\n* Singleton pregnancy,\n* Mothers who speak Finnish or Swedish\n* Mothers who are planning to breastfeed or give breastmilk by bottle to the infant\n* Infants who are expected to be healthy and who will not require BCG vaccination.\n\nExclusion Criteria:\n\n* Participants who lives further than a 2-hour drive from Meilahti, Helsinki, Finland\n* Mothers who are not planning to breastfeed or feed breastmilk by bottle to the infant\n* Mothers who are diagnosed with gestational diabetes, pre-eclampsia or who have been receiving antibiotics during the pregnancy or delivery\n* Premature infants born before the pregnancy week 37\n* Infants, who are born by urgent cesarean section or emergency cesarean section\n* Infants, who receive antibiotics during the first week of life\n* Infants, who are diagnosed with a disease, congenital anomaly or who receive less than 9 Apgar points at 5 minutes.\n* Infants, who receive BCG-vaccine","50 Years",{"count":107,"type":24},[27],"The goal of this clinical trial is to test the ability of different bacterial products in restoring natural gut microbiota in C-section born infants. The main question it aims to answer is:\n\nDo maternally derived strains of bacteria perform better than commercially available probiotic strains in restoring the gut microbiota of C-section born infants? Researchers will compare the gut microbiota of treated infants to that of untreated C-section born infants and untreated vaginally born infants to see if the bacterial treatments cause the microbiota to resemble that of vaginally born infants.\n\nParticipants will be given a bacterial product orally once daily for either one or four weeks and be asked to collect faecal, urine and saliva samples.",[383,384,385,386,387,388,389,390,391,392,31,393,394,215,395],"Infant, Newborn","Gut -Microbiota","Gut Dysbiosis","Cesarean Delivery Affecting Newborn","Cesarean Section","Vaginal Delivery","Gastrointestinal Microbiota","Microbiota, Cesarean Section, Probiotics, Dysbiosis","Feces","Delivery, Obstetric","Microbiology","Humans","Neonate",[397,398,399,400,401,402],"Infant","newborn","cesarean section","neonate","restore","gut microbiota","2025-09-30",{"date":405,"type":39},"2025-10-08",{"date":407,"type":39},"2025-07-17",{"date":409,"type":24},"2035-12-31",{"name":411,"class":46},"University of Helsinki",{"id":413,"slug":414,"hasResults":12,"nctId":415,"briefTitle":416,"officialTitle":417,"acronym":418,"eligibilityCriteria":419,"healthyVolunteers":12,"sex":19,"minAge":55,"maxAge":420,"enrollmentInfo":421,"targetDuration":4,"studyType":25,"phases":423,"briefSummary":425,"conditions":426,"keywords":439,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":449,"lastUpdatePostDateStruct":450,"startDateStruct":452,"completionDateStruct":454,"leadSponsor":456,"locationsCount":47},"100608614","phase-4-modulation-of-gut-microflora-with-rifaximin-to-reduce-high-platelet-reactivity-in-post-acs-patients-on-ticagrelor-100608614","NCT07203846","Modulation of Gut MicroFLORA With Rifaximin to Reduce High Platelet Reactivity in Post-ACS Patients on Ticagrelor","Modulation of Gut Microflora With Rifaximin to Reduce High Platelet Reactivity in Post-Acute Coronary Syndrome Patients on Ticagrelor (FLORA-ACS)","FLORA-ACS","Inclusion criteria:\n\n* Between 18 and 80 years of age\n* History of acute coronary syndrome no sooner than 1 month and no later than 12 months prior to study inclusion\n* Current treatment with ticagrelor (90 mg orally twice a day)\n* High platelet reactivity assessed with multiple electrode aggregometry method (AUC of \\>46 U)\n* Provision of informed consent prior to any study procedures\n\nExclusion criteria:\n\n* History of hypersensitivity to rifaximin or other rifamycin-derived agent\n* Ongoing treatment with rifamycins\n* Platelet count \\\u003C 100×10\\^9\u002FL or \\> 450×10\\^9\u002FL\n* Treatment with antibiotics, probiotics, or glucocorticoids within 3 months prior to study inclusion\n* History of gastrointestinal diseases such as inflammatory bowel disease, bowel obstruction, or gastrointestinal tumor\n* Infection, including gastrointestinal infection, within a month prior to study inclusion\n* History of Clostridium difficile infection\n* Current use of specific medications (warfarin, glycoprotein IIb\u002FIIIa inhibitors, immunosuppressants, bile acid sequestrants, antidiarrheal agents)\n* Impaired liver function classified as Child-Pugh class B or C\n* Hemodynamic instability\n* Pregnancy or breastfeeding\n* Patients considered by the investigator to be uncooperative","80 Years",{"count":422,"type":24},50,[424],"PHASE4","The FLORA-ACS study aims to evaluate the relationship between dysbiosis and high platelet reactivity during treatment with ticagrelor in patients with a history of acute coronary syndromes and investigate the use of rifaximin to eliminate dysbiosis and thus provide effective antiplatelet treatment.",[427,428,31,429,430,431,432,433,434,435,436,437,438],"ACS - Acute Coronary Syndrome","Ticagrelor","Platelet Aggregation","Myocardial Infarction (MI)","Blood Platelets","Drug Effects","Platelet Aggregation Inhibitors","Drug Resistance","Platelet Function Tests","Dysbiosis","Anti-Bacterial Agents","Rifaximin",[440,441,442,443,444,358,445,446,447,448],"high platelet reactivity","HPR","Multiplate aggregometry","multiple electrode aggregometry","MEA","gut flora","eubiotic","16S rRNA sequencing","P2Y12 inhibitor","2025-09-25",{"date":451,"type":39},"2025-10-02",{"date":453,"type":24},"2026-01-01",{"date":455,"type":24},"2027-06-30",{"name":457,"class":46},"Collegium Medicum w Bydgoszczy",{"id":459,"slug":460,"hasResults":12,"nctId":461,"briefTitle":462,"officialTitle":463,"acronym":464,"eligibilityCriteria":465,"healthyVolunteers":18,"sex":79,"minAge":55,"maxAge":466,"enrollmentInfo":467,"targetDuration":4,"studyType":25,"phases":468,"briefSummary":469,"conditions":470,"keywords":473,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":478,"lastUpdatePostDateStruct":479,"startDateStruct":481,"completionDateStruct":483,"leadSponsor":485,"locationsCount":47},"100598972","innate-immunity-microbiota-and-inovative-treatments-in-endometriosis-100598972","NCT07078435","Innate Immunity, MIcrobiota and Inovative Treatments in Endometriosis","Inflammation, Innate Immunity, MIcrobiota and Inovative Treatments in ENDOmetriosis","IMIEndo","Inclusion Criteria:\n\n* Women aged 18-42 years.\n* Surgery scheduled during the luteal phase.\n* Written informed consent provided.\n\nAdditional inclusion criteria for the \"endometriosis\" group:\n\n* Women with confirmed endometriosis and a surgical indication (due to persistent symptoms despite medical treatment and\u002For risk of organ damage).\n* Hormonal therapy discontinued at least one month prior to surgery.\n* Absence of isolated ovarian endometrioma.\n\nControl group inclusion criteria:\n\n\\- Women requiring benign gynecological surgery with no clinical or intraoperative evidence of endometriosis.\n\nNo inclusion criteria (both groups):\n\n* Presence of inflammatory bowel disease (Crohn's disease, ulcerative colitis) or other autoimmune disorders (e.g., lupus, Sjögren's syndrome, antiphospholipid syndrome, rheumatoid arthritis, spondyloarthritis),\n* Use of antibiotics within the month prior to surgery,\n* Recent infection (\\\u003C2 weeks),\n* Ongoing treatment with biologics or immunosuppressants,\n* Contraindication to surgery due to general condition or comorbidities,\n* Hormonal therapy within the month prior to surgery,\n* Abdominopelvic surgery involving peritoneal breach within the previous 6 months,\n* Pregnancy or breastfeeding,\n* Participation in another clinical study (RIPH 1 or 2).\n\nExclusion Criteria:\n\n* Intraoperative impossibility to perform surgery due to local conditions with an unfavorable benefit-risk balance for the patient.\n* Discovery of endometriosis during surgery in the control group.\n* Use of biologics or immunosuppressants within the first year after inclusion in the endometriosis group.\n* Antibiotic use in the month preceding the second stool sample (endometriosis group).","42 Years",{"count":23,"type":24},[27],"Endometriosis is a chronic inflammatory, polygenic, and multifactorial disease affecting approximately 10% of women of reproductive age, corresponding to over one million women in France. Endometriosis profoundly impairs the health and quality of life of affected individuals and carries a significant socio-economic burden, making it a major public health concern. To date, the pathogenesis and prognostic factors of disease progression remain poorly understood. Despite current treatment options, which are based on hormonal therapy or surgery, resistance and recurrence are frequent, underscoring the urgent need for innovative therapeutic strategies.\n\nThe hypothesis of retrograde menstruation of endometrial cells, among other proposed theories, appears insufficient to fully explain the development of the disease. Immunological factors may be implicated. Endometriosis is characterized by the presence of endometriotic tissue outside the uterine cavity- within the peritoneal cavity or at distant sites-forming lesions that, like eutopic endometrium, contain infiltrating immune cells, with varying compositions across menstrual cycle phases. Although data remain scarce, the literature points to several key mechanisms:\n\nInflammation and innate immunity with the dendritic cells, that initiate and orchestrate immune responses, appear to be present in different proportions and exhibit altered phenotypes in endometriotic tissue compared to healthy tissue. Macrophages, essential for phagocytosis, tissue repair, and the resolution of inflammation, also show functional and phenotypic modulation. In particular, efferocytosis-their ability to clear apoptotic cells-is impaired, and an imbalance in M1\u002FM2 polarization has been described, potentially facilitating menstrual cell escape. The local microenvironment is characterized by altered cytokine and chemokine profiles. Natural Killer cells exhibit disrupted expression patterns of activating and degranulation capacity.\n\nMicrobiota: Many studies suggest a potential role for the intestinal microbiota in the initiation and\u002For promotion of endometriosis. Patients frequently exhibit gut dysbiosis, marked by reduced microbial diversity.\n\nResolution of Inflammation: Endometriosis may be associated with defective resolution of inflammation. Resolutive pharmacology involves the use of pro-resolving factors to exert a therapeutic effect by accelerating or stimulating the resolution of inflammation.\n\nThe interplay between local inflammation, the gut microbiota, and disease progression remains incompletely elucidated. A comprehensive phenotypic and functional characterization of immune cells-particularly innate immune cells (dendritic cells, macrophages, Natural Killer cells) - in parallel with microbiome profiling and clinical outcome data, may yield novel insights into disease mechanisms and support the development of pro-resolutive therapeutic strategies that may be of interest in endometriosis.\n\nStudy Design This will be a monocentric (at Grenoble University Hospital), open-label, prospective experimental study with a control arm.\n\nThe primary objective is to identify immune biomarkers associated with endometriosis.\n\nSecondary objectives include:\n\n1. Identification of immune biomarkers associated with clinical outcomes in endometriosis.\n2. Characterization of the immunogenetic KIR\u002FHLA (Killer Immunoglobulin-like Receptors \u002F Human Leukocyte Antigen) system in both study groups.\n3. Analysis of stromal cells, apoptosis, macrophage efferocytosis, and their responsiveness to pro-resolutive factors in both groups.\n4. Identification of a characteristic bacterial gut microbiota profile at diagnosis in women with endometriosis versus controls, and\u002For profiles associated with one-year clinical outcomes (favorable vs unfavorable), as well as temporal microbiota trajectories over one year in relation to clinical response.\n\nStudy Population:\n\nThe study will include women undergoing surgery for endometriosis versus control women undergoing benign gynecological surgery with no known history or intraoperative evidence of endometriosis, aged 18 to 42.\n\nStudy Procedures:\n\nWomen in the endometriosis group will undergo collection of endometriotic lesions, adjacent tissue, eutopic endometrium, and peritoneal lavage during surgery. Controls will provide biopsies of eutopic endometrium, unaffected peritoneum, and peritoneal lavage. For both groups, peripheral blood samples will be collected during routine care and stool samples obtained at baseline (Day 0). For the endometriosis group, a second stool sample will be collected at 12 months (M12).\n\nA clinical evaluation will be performed at inclusion for all participants and repeated at one year for the endometriosis group. Participation for control group subjects is limited to the day of surgery, whereas endometriosis group subjects will be followed for 12 months.",[471,472,31],"Endometriosis","Immunity",[474,475,476,477,328],"endometriosis","surgery","immunity","efferocytose","2025-08-25",{"date":480,"type":39},"2025-09-02",{"date":482,"type":24},"2025-09-09",{"date":484,"type":24},"2027-09-30",{"name":486,"class":46},"University Hospital, Grenoble",{"id":488,"slug":489,"hasResults":12,"nctId":490,"briefTitle":491,"officialTitle":492,"acronym":4,"eligibilityCriteria":493,"healthyVolunteers":18,"sex":19,"minAge":55,"maxAge":4,"enrollmentInfo":494,"targetDuration":4,"studyType":156,"phases":4,"briefSummary":496,"conditions":497,"keywords":500,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":502,"lastUpdatePostDateStruct":503,"startDateStruct":505,"completionDateStruct":507,"leadSponsor":509,"locationsCount":47},"100540662","characteristics-of-intestinal-microbiome-following-pancreatic-surgery-100540662","NCT06319755","Characteristics of Intestinal Microbiome Following Pancreatic Surgery","Characteristics of Intestinal Microbiome Following Pancreatic Surgery - a Prospective Case Controlled Exploratory Study","Inclusion Criteria:\n\n* Adults (aged equal to or greater than 18 years) having had pancreatoduodenectomy (Whipple's) surgery between April 2018 - December 2023 for curative intent and received post-operative clinical management at Royal Prince Alfred Hospital, (post-surgical participants), and\n* Healthy adults matched by age, sex, body mass index and smoking status\n\nExclusion Criteria:\n\n* Aged less than 18 years\n* Are unable to complete the questionnaires or testing due to language or cognitive limitations\n* Have active or recurring pancreatic cancer, or where the surgery was for non-curative intent\n* Have other gastrointestinal conditions that could affect gut symptoms or microbiome such as Inflammatory Bowel disease, Irritable Bowel Syndrome Coeliac disease, or are currently pregnant or breastfeeding\n* Are currently taking medications or diet that can affect gut symptoms or microbiome",{"count":495,"type":24},20,"The goal of this observational study is to learn about intestinal microbiome structure and function in individuals who have undergone a pancreatoduodenectomy and compare to healthy matched controls.\n\nThe primary objectives of the study are:\n\n1. To explore and describe any differences in the gut microbiota especially Shannon diversity index\n2. To conduct functional profiling by exploring and describing any differences in functional metabolites produced in the gut in people having had pancreatoduodenectomy greater than 6 months ago compared to healthy matched controls.\n\nParticipants will be asked to complete the following:\n\n* Three-day food, bowel and medication diary (see Protocol appendix 5)\n* Gastrointestinal Symptom Rating Scale (see Protocol appendix 6)\n* Quality of life questionnaire (see Protocol appendix 7)\n* Stool sample test using Microba Insight TradeMark (a small swab is taken from soiled toilet paper, sealed in a room-temperature storage capsule and mailed to the testing laboratory)",[498,31,499],"Pancreatic Cancer","Pancreatoduodenectomy",[501],"matched case control study","2025-07-21",{"date":504,"type":39},"2025-07-24",{"date":506,"type":39},"2024-08-01",{"date":508,"type":24},"2025-08",{"name":510,"class":46},"Royal Prince Alfred Hospital, Sydney, Australia",{"id":512,"slug":513,"hasResults":12,"nctId":514,"briefTitle":515,"officialTitle":516,"acronym":517,"eligibilityCriteria":518,"healthyVolunteers":12,"sex":19,"minAge":519,"maxAge":520,"enrollmentInfo":521,"targetDuration":4,"studyType":25,"phases":523,"briefSummary":524,"conditions":525,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":528,"lastUpdatePostDateStruct":529,"startDateStruct":530,"completionDateStruct":532,"leadSponsor":534,"locationsCount":4},"100599314","impact-of-colostrum-oropharyngeal-immunotherapy-on-postnatal-growth-in-preterm-infants-100599314","NCT07082881","Impact of Colostrum Oropharyngeal Immunotherapy on Postnatal Growth in Preterm Infants","Impact of Colostrum Oropharyngeal Immunotherapy on Postnatal Growth in Preterm Infants Based on Early Gut Microbiota-Host Interaction Patterns: A Protocol for a Randomized Controlled Trial","IOCOIOPGIPI","Inclusion Criteria:\n\n1. Gestational age \\\u003C32 weeks and birth weight \\\u003C1500 g;\n2. admitted to the NICU of one of the five hospitals mentioned above within 24 h of birth; and\n3. able to initiate the protocol within 72 h of birth and continuously provide adequate colostrum until the end of the protocol.\n\nExclusion Criteria:\n\n1. Death within 48 h;\n2. severe birth asphyxia (defined as umbilical artery\u002Ffirst-hour arterial blood gas pH \\\u003C 7.0);\n3. birth with severe gastrointestinal malformations (e.g., intestinal atresia, tracheoesophageal fistula, malrotation of the intestines, and Hirschsprung's disease);\n4. prenatal diagnosis of congenital chromosomal abnormalities or suspected congenital genetic metabolic diseases; and\n5. maternal substance abuse or contraindications to breastfeeding (e.g., HIV).","0 Days","1 Day",{"count":522,"type":24},220,[27],"The goal of this clinical trial is to ascertain whether oropharyngeal administration of colostrum contributes to postnatal growth in very preterm infants (those born before 32 weeks of gestation). The main questions it aims to answer are:\n\nCan Oropharyngeal administration of colostrum effectively lower the incidence rate of extrauterine growth restriction (EUGR) in participants? Does oropharyngeal colostrum intervention bring about changes in the early gut microbiota of participants? Researchers will conduct a comparative analysis between colostrum and a placebo (normal saline) to investigate whether oropharyngeal administration of colostrum has a beneficial effect on the postnatal growth of participants.\n\nParticipants will:\n\nInitiation of oropharyngeal colostrum administration will take place within 48 - 72 hours after birth, and the treatment will be administered continuously for a period of 5 days.\n\nStool samples will be collected from the participants both before and after the intervention.\n\nParticipants will be required to maintain a diary to document their basic characteristics and clinical outcomes.",[526,527,31],"Growth Failure","Preterm Birth","2025-07-16",{"date":504,"type":39},{"date":531,"type":24},"2025-09-01",{"date":533,"type":24},"2028-09-30",{"name":535,"class":46},"Suqian First Hospital",{"id":537,"slug":538,"hasResults":12,"nctId":539,"briefTitle":540,"officialTitle":541,"acronym":4,"eligibilityCriteria":542,"healthyVolunteers":18,"sex":19,"minAge":519,"maxAge":378,"enrollmentInfo":543,"targetDuration":4,"studyType":25,"phases":545,"briefSummary":547,"conditions":548,"keywords":4,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":553,"lastUpdatePostDateStruct":554,"startDateStruct":556,"completionDateStruct":558,"leadSponsor":560,"locationsCount":47},"100308670","phase-1-vaginal-microbiome-seeding-and-health-outcomes-in-cesarean-delivered-neonates-100308670","NCT03298334","Vaginal Microbiome Seeding and Health Outcomes in Cesarean-delivered Neonates.","Vaginal Microbiome Seeding and Health Outcomes in Cesarean-delivered Neonates: a Randomized Controlled Trial","Inclusion Criteria for Mother:\n\n* Scheduled for cesarean delivery at ≥ 37 weeks\n* Pregnant with single fetus, in good general health, age 18 years or older\n* Negative maternal testing for infections transmitted through vaginal and\u002For other body fluids performed as standard of care tests in early pregnancy\n* Negative testing for Group B strep at 35-37 weeks gestation\n* Vaginal pH ≤ 4.5 indicative of Lactobacillus-dominated vaginal microbiota\n* No maternal or fetal complications that may inhibit the ability to perform microbiome restoration per protocol\n* English or Spanish speaking\n* Negative maternal testing for Gonorrhea, Chlamydia, Hepatitis B, Hepatitis C, Syphilis, and HIV at 35 weeks gestation or later\n* Women aged 18-29 years must have a normal Pap test within 3 years\n* Women aged 30-65 years must have a normal Pap test and an HPV test (co-testing) within 5 years or FDA-approved primary hrHPV testing alone within 5 years or a normal Pap test alone within 3 years\n* Negative maternal testing for SARS-CoV-2 for the delivery admission performed as standard of care test at the Inova Health System.\n\nInclusion Criteria for Infant:\n\n* Infant condition after delivery requires no more than standard neonatal resuscitation\\* or is otherwise medically unable to receive the full VMT procedure\n\n\\[\\*\\] Standard neonatal resuscitation may include: tactile stimulation, bulb suction, oxygen without positive pressure, or drying\n\nExclusion Criteria for Mother:\n\n* Delivery at a hospital other than Inova Health System\n* Cesarean delivery scheduled for active infection that would have interfered with vaginal delivery such as genital herpetic lesions\n* Rupture of membranes prior to scheduled cesarean delivery\n* Bacterial vaginosis within 30 days of cesarean delivery\n* Symptomatic urinary tract infection within 30 days of cesarean delivery\n* Antibiotic therapy within 30 days of cesarean delivery (exclusive of medication use for prophylaxis at the time of surgery)\n* Symptoms on admission suggesting Chorioamnionitis, e.g. maternal fever, fundal tenderness\n* Symptoms on delivery admission of possible vaginal infection such as genital herpetic lesions\n* History of genital HSV\n* History positive testing for Group B strep infection\n* History of a child with a diagnosis of Group B strep sepsis\n* Pregnancy a result of donor egg or surrogacy\n* Preexisting history of Type I or Type II Diabetes\n* Maternal history of documented genital HPV infection, positive HPV testing or genital warts on physician examination\n* Positive maternal testing for SARS-CoV-2 within 30 days of delivery or symptoms on admission suggesting potential Covid-19 infection",{"count":544,"type":24},600,[84,546],"PHASE2","Neonates delivered by scheduled Cesarean Section will be randomized to receive vaginal seeding (exposing the infant to Mother's vaginal flora) or sham. Infants will be followed for three years to examine health outcomes including microbiome development, immune development, metabolic outcomes, and any adverse events.",[386,549,550,31,551,552],"Obesity, Childhood","Intestinal Microbiome","Host Microbial Interactions","Gastrointestinal Microbiome","2025-06-04",{"date":555,"type":39},"2025-06-08",{"date":557,"type":39},"2018-07-01",{"date":559,"type":24},"2029-04",{"name":561,"class":562},"National Institute of Allergy and Infectious Diseases (NIAID)","NIH",{"id":564,"slug":565,"hasResults":12,"nctId":566,"briefTitle":567,"officialTitle":568,"acronym":569,"eligibilityCriteria":570,"healthyVolunteers":12,"sex":79,"minAge":105,"maxAge":378,"enrollmentInfo":571,"targetDuration":4,"studyType":156,"phases":4,"briefSummary":573,"conditions":574,"keywords":4,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":579,"lastUpdatePostDateStruct":580,"startDateStruct":582,"completionDateStruct":584,"leadSponsor":586,"locationsCount":47},"100527218","norwegian-microbiota-study-in-anorexia-nervosa-100527218","NCT06144905","Norwegian Microbiota Study in Anorexia Nervosa","Gut Microbiota Alterations in Anorexia Nervosa - Paving the Way for Personalized Prebiotic Treatment Strategies","NORMA","Inclusion Criteria AN group\n\n1. Sex: Female\n2. Age: 16-50 years\n3. BMI: \\\u003C18.5 kg\u002Fm2\n4. fulfilling ICD-10 criteria for AN\n5. currently referred to specialized inpatient nutritional treatment for AN\n6. able to understand the Norwegian questionnaires.\n\nExclusion Criteria AND group:\n\n1. history of inflammatory bowel disease, celiac disease, or GI tract surgery;\n2. treatment with oral antibiotics the past two months\n3. high intake of probiotic supplements over the past two months.\n\nInclusion criteria control group\n\n1. Sex: Female\n2. Age: 16-50 years\n3. BMI: \\>= 18.5 \\& \\\u003C 27\n4. able to understand the Norwegian questionnaires.\n\nExclusion Criteria AND group:\n\n1. history of inflammatory bowel disease, celiac disease, or GI tract surgery;\n2. treatment with oral antibiotics the past two months\n3. high intake of probiotic supplements over the past two months.",{"count":572,"type":24},180,"Anorexia nervosa (AN) is a serious mental disorder occurring mainly in women. AN is characterized by severely restricted food-intake and subsequent low weight. The disease burden for the individual is high with medical complications and psychiatric comorbidities. Despite decades of research, there are large gaps in the understanding of the biological aspects of AN and lack of effective interventions. Current clinical treatment is associated with gastrointestinal problems, high rates of relapse and poor outcome causing long-term sickness absence and disability. During the COVID19 pandemic the prevalence and severity of AN has spiked. Therefore, there is great need of novel strategies for AN treatment, that can be easily implemented in the clinic without adding complexity to the standard care of treatment. During the resent years it has been proposed that mental disorders might be treated via manipulating the composition and function of the microbes that live in the gut (the microbiota) by adding or restricting fermentable nutrients (prebiotics) in the diet. However, in order to use prebiotics to treat the microbiota in AN patients, more knowledge is needed on how the AN microbiota is affected by the current standard care treatment. Whether prebiotics can be useful for normalizing AN microbiota remains to be established. The overall aim of the \"Norwegian study of Microbiota in Anorexia Nervosa\" (NORMA) is to join forces of researchers, clinical health care services and voluntary sector in a transdiciplinary approach to improve the understanding of the role of the gut microbiota in AN patients. The current project will include a clinical trial in AN patients and experimental studies to screen novel prebiotics for their ability to modify and normalize AN derived microbiota. The long-term goal of the project is to pave the way for a targeted and clinically feasible individualized treatment for better tolerable weight-restoration and improved health in AN patients.",[575,576,31,577,578],"Anorexia Nervosa","Mental Health Issue","Diet","Gastrointestinal Problems","2025-05-20",{"date":581,"type":39},"2025-05-23",{"date":583,"type":39},"2023-09-24",{"date":585,"type":24},"2043-09",{"name":587,"class":46},"Norwegian University of Life Sciences",{"id":589,"slug":590,"hasResults":12,"nctId":591,"briefTitle":592,"officialTitle":592,"acronym":4,"eligibilityCriteria":593,"healthyVolunteers":12,"sex":19,"minAge":55,"maxAge":4,"enrollmentInfo":594,"targetDuration":4,"studyType":156,"phases":4,"briefSummary":596,"conditions":597,"keywords":4,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":600,"lastUpdatePostDateStruct":601,"startDateStruct":603,"completionDateStruct":605,"leadSponsor":607,"locationsCount":609},"100590501","exploring-clinical-characteristics-of-liver-disease-patients-based-on-digestive-metabolic-exhaled-air-100590501","NCT06968234","Exploring Clinical Characteristics of Liver Disease Patients Based on Digestive Metabolic Exhaled Air","Inclusion Criteria:\n\n① Patients diagnosed with chronic liver disease or cirrhosis through liver biopsy pathology or clinical laboratory and imaging examinations;\n\n② Undergo molecular breath testing within one week of admission.\n\nExclusion Criteria:\n\n* Patients who have received antibiotic treatment within one month; ② Patients with severe pulmonary diseases, such as chronic obstructive pulmonary disease (COPD), asthma, or lung malignancies that have not been clinically cured; ③ Patients who are unable to successfully complete the molecular breath test.",{"count":595,"type":24},1000,"Cirrhosis is a common digestive system disease and represents the final stage of the progression of various chronic liver diseases. During cirrhosis, the intestinal microenvironment is affected due to liver damage and increased portal venous pressure. Displacement of gut microbiota is closely related to the occurrence and development of cirrhosis. Disruption of the gut microbiota is associated with changes in the levels of nitric oxide (NO), hydrogen (H₂), methane (CH₄), and hydrogen sulfide (H₂S). Breath testing is an emerging method for assessing gut microbiota. This project aims to investigate the characteristics and prognosis of patients with chronic liver disease by detecting exhaled breath markers such as nitric oxide (NO), hydrogen (H₂), methane (CH₄), and hydrogen sulfide (H₂S), in conjunction with results from serological tests, gut microbiota analysis, and radiomics. The goal is to identify new diagnostic biomarkers and therapeutic targets, to recognize high-risk patients at an early stage, and to improve patient survival rates and quality of life.",[598,31,599],"Cirrhosis","Breath Tests","2025-05-05",{"date":602,"type":39},"2025-05-13",{"date":604,"type":39},"2025-03-01",{"date":606,"type":24},"2028-12",{"name":608,"class":46},"Shanghai Zhongshan Hospital",3,{"id":611,"slug":612,"hasResults":12,"nctId":613,"briefTitle":614,"officialTitle":615,"acronym":616,"eligibilityCriteria":617,"healthyVolunteers":18,"sex":19,"minAge":55,"maxAge":4,"enrollmentInfo":618,"targetDuration":4,"studyType":25,"phases":619,"briefSummary":620,"conditions":621,"keywords":4,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":624,"lastUpdatePostDateStruct":625,"startDateStruct":627,"completionDateStruct":629,"leadSponsor":631,"locationsCount":47},"100578312","effects-of-endocrine-disruptors-on-the-gut-microbiota-and-assessment-of-their-impact-on-colorectal-cancer-development-permica-100578312","NCT06809660","Effects of Endocrine Disruptors on the Gut Microbiota and Assessment of Their Impact on Colorectal Cancer Development (PERMICA)","Effects of Endocrine Disruptors on the Gut Microbiota and Assessment of Their Impact on Colorectal Cancer Development","PERMICA","Inclusion Criteria:\n\n* Scheduled endoscopy during the inclusion visit or within 18 months following this consultation.\n* Signed consent from the patient after clear and fair information about the study is provided.\n* Patient is free of guardianship, curatorship, or dependency.\n* Patient is covered by a social security system or through a third party.\n\nExclusion Criteria:\n\n* Patients receiving treatment for chronic inflammatory bowel disease;\n* Patients with hereditary colorectal cancer;\n* Use of antibiotics, probiotics, or prebiotics within four weeks prior to stool sample collection;\n* Patients who have undergone neoadjuvant chemotherapy or radiotherapy;\n* Patients who have had previous surgical resection;\n* Patients under enhanced protection: minors, individuals deprived of liberty by judicial or administrative decision, individuals residing in healthcare or social institutions, and adults under legal protection;\n* Pregnant and\u002For breastfeeding women.\n\nExclusion Criteria During Study Participation:\n\n* Patients presenting any of the following during their participation in the study will be excluded:\n* Use of antibiotics, probiotics, or prebiotics before stool collection (between inclusion and stool collection, which may occur within the month);\n* Endoscopy not performed within 18 months following inclusion;\n* Failure to send\u002Freceive stool samples",{"count":57,"type":24},[27],"Colorectal cancer is the third most common cancer worldwide, yet it was the second leading cause of cancer-related deaths in 2020. The average French population faces a colorectal cancer risk partly linked to lifestyle factors. The majority of colorectal cancer cases (approximately 85%) are not caused by hereditary mutations. Environmental factors, such as lifestyle or diet (notably through endocrine disruptors), can affect the gut microbiota (a collection of microorganisms - bacteria, viruses, parasites, and fungi - residing in the intestinal environment) and lead to disturbances in its composition, referred to as dysbiosis. While the mechanisms underlying dysbiosis associated with colorectal cancer remain poorly understood, the involvement of certain ingested substances, known as xenobiotics, is increasingly suspected, including endocrine disruptors. Among the most common endocrine disruptors found in water and food are parabens and phthalates, which will be examined in detail in this study. These substances may be directly involved in the development of colorectal cancer and in response to its treatment.\n\nThe main objective of this studie is to characterize the relationship between colorectal cancer diagnosis, activity\u002Fcomposition of the gut microbiota, and patients' exposure to selected endocrine disruptors, particularly parabens and phthalates.",[622,623,31,436],"Colorectal Cancer (CRC)","Endocrine Disruptors","2025-02-12",{"date":626,"type":39},"2025-02-13",{"date":628,"type":39},"2025-01-21",{"date":630,"type":24},"2034-01-21",{"name":632,"class":46},"Poitiers University Hospital",{"id":634,"slug":635,"hasResults":12,"nctId":636,"briefTitle":637,"officialTitle":638,"acronym":639,"eligibilityCriteria":640,"healthyVolunteers":12,"sex":19,"minAge":55,"maxAge":420,"enrollmentInfo":641,"targetDuration":520,"studyType":156,"phases":4,"briefSummary":642,"conditions":643,"keywords":646,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":650,"lastUpdatePostDateStruct":651,"startDateStruct":653,"completionDateStruct":655,"leadSponsor":657,"locationsCount":47},"100464104","bern-human-organoid-study-to-study-host-microbe-interaction-100464104","NCT05323357","Bern Human Organoid-Study to Study Host-microbe Interaction","Establishment of Human Organoid Lines as a Tool to Dissect Molecular Pathways of Host-microbiota Interactions","humorg","Inclusion Criteria:\n\n* Signed informed consent\n* Indication for upper or lower endoscopic procedure\n* Ability to understand and follow study procedures and understand informed consent\n* Age 18-80 years\n* Negative pregnancy test result prior to study enrollment of female study participants (test will be performed prior to enrollment)\n* BMI between 18.5 and 30 kg\u002Fm2\n\nExclusion Criteria:\n\n* Disease known to chronically affect gut microbiota, gut epithelium or gut-associated immune system, namely inflammatory bowel disease, diverticulitis, microscopic colitis, liver cirrhosis, malignancy within the digestive tract, systemic sclerosis, coeliac disease, common-variable immunodeficiency, diabetes mellitus\n* Medication with immunosuppressants (e.g. corticoids, biological therapy)\n* Current diagnosis of a hematological disorder (e.g. anemia with hemoglobin \\\u003C7 g\u002Fdl, leukemia) or any other absolute contraindication for blood draw\n* Women who are pregnant\n* Serious coagulation disorder, relevant thrombocytopenia (\\\u003C50'000\u002Ful), double platelet-inhibition, oral anticoagulation (ASS therapy is possible)\n* Known or suspected non-compliance, drug, or alcohol abuse\n* Inability to follow the procedures of the study, e.g., due to language problems, psychological disorders, dementia, etc. of the participant\n* Previous enrolment into the current study\n* Enrolment of the investigator, his\u002Fher family members, employees, and other dependent persons\n* Inability or unwillingness to provide blood samples and tissue samples (biopsies)\n* Participants taking oral anticoagulant or with bleeding disorders who would be at much higher risk of bleeding after biopsy samples or who are contraindicated for an endoscopic examination\n* Patients unable to give informed consent\n* Patients that have been under antibiotic therapy in the last 4 weeks\n* Participation in other clinical study interfering with study procedures\n* Potential study participants that wish not to be informed about random results acquired during the study (e.g., during endoscopy or genetic analysis) relevant for their health and for prevention of diseases",{"count":107,"type":24},"The human body inhabits a complex consortium of different microbes which together form the microbiota. Virtually every surface of the human body is colonized by a distinct microbiota, forming complex communities. An increasing number of research results indicates that changes in the microbiota can have vast effects on the health of its host.\n\nMost studies investigating the microbiota were conducted on animals, as many interventions and investigations cannot be performed on humans due to ethical considerations. This raises the question if findings from experimental studies are translational and can benefit patients. That becomes especially apparent when trying to dissect molecular mechanisms involved in this fine-tuned interplay between nutrients, the microbiota, and its host.\n\nBy establishing human organoid cultures from the large and small intestine that can be exposed to microbes and\u002For microbial products with subsequent transcriptomic, epigenetic and immunological analysis, the investigators aim to generate findings with high translational potential with new insights into the complex interaction of the microbiota, the host and its immune system.",[644,645,31],"Organoids","Allergy and Immunology",[647,648,649],"Enteroids","Host-Microbiota","Mucosal Immunology","2024-12-05",{"date":652,"type":39},"2024-12-11",{"date":654,"type":39},"2022-03-31",{"date":656,"type":24},"2026-03-30",{"name":658,"class":46},"Insel Gruppe AG, University Hospital Bern",{"id":660,"slug":661,"hasResults":12,"nctId":662,"briefTitle":663,"officialTitle":664,"acronym":665,"eligibilityCriteria":666,"healthyVolunteers":18,"sex":19,"minAge":55,"maxAge":4,"enrollmentInfo":667,"targetDuration":4,"studyType":156,"phases":4,"briefSummary":669,"conditions":670,"keywords":4,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":672,"lastUpdatePostDateStruct":673,"startDateStruct":675,"completionDateStruct":677,"leadSponsor":679,"locationsCount":47},"100485857","microbiota-and-pancreatic-cancer-cachexia-100485857","NCT05606523","Microbiota and Pancreatic Cancer Cachexia","Can Fecal Microbiota Transplantation of Cachectic Patients with Pancreas Cancer Impair Body Weight Gain in Germ-free Mice? the EXTRA Study","EXTRA","Inclusion Criteria:\n\nPatients with pancreatic cancer (n=12)\n\n* ≥18 years and\n* Newly diagnosed of pancreatic adenocarcinoma (local or metastatic) and\n* Tube feeding or parenteral nutrition ≤ 14 days\n\nCachectic pancreatic cancer patients (n=6)\n\n* Cachexia according to the Fearon criteria 1: involuntary weight loss \\>5% over the last 6 months, or any level of weight loss \\>2% and a BMI \\\u003C20 kg\u002Fm2 or sarcopenia. Sarcopenia will be diagnosed by BIA (fat-free mass index is \\\u003C17 kg\u002Fm2 in men and \\\u003C15 kg\u002Fm2 in women) 81, and not by CT, as it is faster and can be performed at the bedside of the patient. Non-cachectic pancreatic cancer patients (n=6)\n* Normal nutritional state: weight stability (± 2% of habitual weight) over the last 6 months, no anorexia before the diagnosis (appetite rating on a visual analogue scale of 100mm), no known impaired glucose tolerance.\n\nHealthy matched subjects (n=12)\n\n* ≥18 years and\n* BMI between 18.5 and 30 kg\u002Fm2 and\n* Absence of chronic or acute disease and\n* Matching for gender and age (± 5 years) with an included pancreatic cancer patient\n\nExclusion Criteria:\n\n* \\\u003C 18 years or\n* Inability to give consent or\n* Insufficient knowledge of project language (French, German) or\n* Pancreatic adenocarcinoma already treated by chemo- or radiotherapy, or major surgery as duodenopancreatectomy or biliary diversion\n* Known rheumatologic or immunologic diseases\n* Therapeutic antibiotics or immunosuppressive drugs (for instance glucocorticoids, cytostatics, antibodies) in the 30 days preceding the inclusion",{"count":668,"type":24},24,"This monocentric study aims at evaluating the effects of fecal microbiota transplantation from newly diagnosed cachectic and non-cachectic pancreatic cancer patients, and healthy volunteers on several cachexia-related parameters of germ-free mice.",[498,31,671],"Cachexia","2024-12-03",{"date":674,"type":39},"2024-12-06",{"date":676,"type":39},"2022-08-01",{"date":678,"type":24},"2025-04-30",{"name":680,"class":46},"Genton Graf Laurence",{"id":682,"slug":683,"hasResults":12,"nctId":684,"briefTitle":685,"officialTitle":686,"acronym":687,"eligibilityCriteria":688,"healthyVolunteers":18,"sex":79,"minAge":55,"maxAge":689,"enrollmentInfo":690,"targetDuration":4,"studyType":25,"phases":692,"briefSummary":693,"conditions":694,"keywords":700,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":702,"lastUpdatePostDateStruct":703,"startDateStruct":705,"completionDateStruct":707,"leadSponsor":708,"locationsCount":47},"100568593","the-effects-of-night-shift-work-on-health-across-the-menstrual-cycle-100568593","NCT06683248","The Effects of Night Shift Work on Health Across the Menstrual Cycle","The Effects of Night Shift Work on Health Across the Menstrual Cycle: a Pilot Study","MENSLEEP","Inclusion Criteria:\n\n\\- Healthy\n\nExclusion Criteria:\n\n* Use of hormonal contraceptives\n* Chronic disease\n* Regular use of nicotine\n* Use of medication\n* Consumes excessive amounts of alcohol or coffee","35 Years",{"count":691,"type":24},60,[27],"The study aims to investigate the effects of sleep deprivation on women's health across different phases of the menstrual cycle.",[695,696,697,698,31,699],"Sleep Deprivation","Menstrual Cycle","Brain Health","Metabolism","Immune System",[701],"Estrogen","2024-11-11",{"date":704,"type":39},"2024-11-14",{"date":706,"type":39},"2022-04-25",{"date":332,"type":24},{"name":709,"class":46},"Uppsala University"]